151. Sarcoidosis during infliximab therapy for Crohn’s disease
- Author
-
Masaru Honma, Akemi Ishida-Yamamoto, Yutaka Kohgo, Hajime Iizuka, Tomonori Ashida, Hidetoshi Takahashi, Kazuhiro Kaneta, and Yoshinobu Ohsaki
- Subjects
musculoskeletal diseases ,Crohn's disease ,medicine.medical_specialty ,Pathology ,medicine.diagnostic_test ,business.industry ,Dermatology ,General Medicine ,Disease ,medicine.disease ,Infliximab ,Psoriasis ,Rheumatoid arthritis ,Skin biopsy ,Erythematous plaque ,medicine ,Sarcoidosis ,business ,medicine.drug - Abstract
Tumor necrosis factor-alpha (TNF-alpha) antagonists are effective for inflammatory diseases, such as Crohn's disease, rheumatoid arthritis (RA) and psoriasis. Although TNF-alpha antagonists are also useful for sarcoidosis, paradoxical occurrence of sarcoidosis or sarcoidal reaction may be observed. We report a Crohn's disease patient, who developed sarcoidosis during infliximab therapy. A 35-year-old man had been receiving infliximab for 7 months for Crohn's disease. He developed cough and fever, accompanied by an infiltrated erythematous plaque on his right knee. The chest radiography, skin biopsy and laboratory findings were all consistent with sarcoidosis.
- Published
- 2010
- Full Text
- View/download PDF